Covestor’s Trevi Therapeutics TRVI Stock Holding History

Covestor’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Buy	43 +31	+258%	+$451	﹤0.01%	2355
2026 Q1	$0	Buy	+12	New	+$134	﹤0.01%	2776

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Covestor's TRVI Position: Q2 2026 in Review

Covestor increased its Trevi Therapeutics (TRVI) stake by 258% in Q2 2026, buying an estimated $451 and bringing the position to 43 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2355.

Covestor first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Covestor held 43 shares of Trevi Therapeutics worth $1K as of Q2 2026.
Covestor bought 31 Trevi Therapeutics shares in Q2 2026, an estimated $451.
Trevi Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2355 holding.
Covestor first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.